EUCTR2016-004307-30-GB进行中（未招募）1 期
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Phase 2, Dose Ranging Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral Litoxetine 10mg,20mg and 40mg Twice Daily (BID) versus Placebo in Women with Mixed Urinary Incontinence - IXA-CSP-001 Litoxetine v Placebo in Urinary Incontinence 2016-12-09 V1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Ixaltis SAS
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Willing to provide written informed consent
- •2. Have symptoms of urinary incontinence for at least 3 consecutive months
- •3. Have at least 7 incontinence episodes per week in the diary entries for the Screening Period of which at least 3 episodes per week are defined as stress urinary incontinence. The Patient Perception of Intensity of Urgency Scale (PPIUS) will be completed when subjects report an event in the electronic diary (e-diary)
- •4. Have an Investigator-confirmed urinary leakage from the urethral meatus synchronous with effort, eg, coughing or straining as an objective evidence of the stress component of incontinence. The urge incontinence component must be confirmed by the subject diaries during the Screening Period, using the PPIUS
- •5. Subject is ambulatory and able to use the toilet independently
- •6. If subjects use pelvic floor exercises, subjects must have been on a stable exercise and activity regime for at least 3 months prior to Screening and that regime must remain stable during the treatment period
- •7. Subject has a body mass index = 19 kg/m2 but < 31 kg/m2
- •8. Subjects must have a pre-dose mean systolic/diastolic blood pressure of = 140/90 mmHg before randomization can occur
- •9. Subjects must not be pregnant, lactating, or actively trying to become
- •pregnant, Subjects who are premenopausal and of childbearing potential must use a medically acceptable and effective method of birth control for the duration of the study, which can include:
- •a. Having a male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject
- •b. Use of double-barrier methods of contraception; condoms with the use of caps (with spermicide) and intra-uterine devices are acceptable
- •c. Use of hormonal contraceptives (oral, depots, patches, etc.) with double-barrier methods of contraception as outline above
- •d. True abstinence: When this is in line with the preferred and usual lifestyle of the subject (period abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
- •10. Subjects taking oral contraceptives or hormone replacement therapy must have a stable dose and regimen for = 3 months prior to entry into the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. History of anti-incontinence surgery in past 12 months
- •2. Use of Botox for urge urinary incontinence in the past 12 months
- •3. Grade III/IV pelvic organ prolapse; defined per clinical practice
- •4. History of interstitial cystitis or bladder-related pain
- •5. History of pelvic prolapse repair (cystocele or rectocele) or urethral
- •diverticulectomy within 12 months of Screening
- •6. Subjects with concurrent (at Screening), recent (within 30 days), chronic, or recurrent (> 4 per year) urinary tract infections (positive dipstick for urinary tract infection and abnormal microscopic evaluation, signs and symptoms) or unevaluated microhematuria
- •7. History of diagnosed gastrointestinal obstructive disorders
- •8. Chronic severe constipation
- •9. History of radiation cystitis or history of pelvic irradiation
- •10. Electrostimulation, biofeedback, or bladder training therapy (behavioural therapy), during the previous month prior to Screening, or the intention to initiate such therapies during the study. Pessaries and implants are also excluded.
- •11. Postvoid residual (PVR) urine volume > 150 mL
- •12. Diagnosis of dementia
- •13. Diagnosis of epilepsy
- •14. Diagnosis of acute narrow-angle glaucoma
- •15. History of mania or diagnosis of bipolar disorder, and/or seizures
- •16. Subjects with uncontrolled hypertension
- •17. Documented history of myocardial infarction, unstable angina, and/or has undergone coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty in the past year
- •18. Congestive heart failure (New York Heart Association Class III or IV heart failure
- •19. Any concurrent condition or any clinically significant abnormality on the Screening physical examination, laboratory tests, electrocardiogram (ECG; including ischemic heart disease), Hepatitis B or C, which, in the opinion of the Investigator, may affect the interpretation of efficacy or safety data, or which otherwise contraindicates participation in a clinical study with litoxetine:
- •a. Hypersensitivity to litoxetine or any of its ingredients
- •b. History of clinically significant drug hypersensitivity
- •c. Subjects with current (within 2 years) urogenital neoplasms or malignancies including bladder, uterine or cervical cancer
- •d. Subjects with neuropathology that could affect the lower urinary tract or nerve supply, including but not limited to multiple sclerosis, stroke,Parkinsonism, or spinal cord injury
- •e. Subjects with diabetes insipidus
- •f. Clinically significant or unstable, endocrine, hepatic, renal, immunologic, or lung disease (ie, active chronic obstructive pulmonary disease, active seasonal allergic rhinitis), or malignancy other than nonmelanomatous skin cancer
- •20. Severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73m2)
- •21. Severe hepatic impairment (Child-Pugh B or greater)
- •22. Subjects who are on current treatment for depression
- •23. Use of the following medications: nonselective irreversible monoamineoxidase inhibitors, cytochrome P450 (CYP)1A2 inhibitors (such as fluvoxamine, ciprofloxacin, or enoxacin), pimozide and thioridazine, and any other medication that would be considered a safety risk for co-administration with litoxetine
- •24. Use of any pharmacologic agent used to treat symptoms of urinary incontinence
- •25. History of an addiction to drugs or alcohol within 5 years prior to Screening or of alcohol or substance abuse within the past year, as determined by the Investigator
- •26. Participation in a clinical study within the month prior to Screeni
研究者
相似试验
进行中（未招募）
1 期
A double-blind, randomized, placebo-controlled, parallel-group trial of AP30663 given in a vein to patients with atrial fibrillation to restore normal heart rhythm (cardioversion)MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2018-004445-17-DKAcesion Pharma ApS108
进行中（未招募）
不适用
A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Treatment Period. - BICOChronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-002151-25-FIAstraZeneca AB40
进行中（未招募）
不适用
A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Treatment Period.Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-002151-25-DKAstraZeneca AB40
进行中（未招募）
不适用
Investigating Pitavastatin for High Cholesterol in Childrehigh-risk hyperlipidaemiaMedDRA version: 14.1Level: PTClassification code 10062060Term: HyperlipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10016205Term: Familial hyperlipidaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: LLTClassification code 10049593Term: Familial hypercholesterolaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-004964-32-NOKowa Research Europe, Ltd.96
进行中（未招募）
不适用
Investigating Pitavastatin for High Cholesterol in ChildreEUCTR2011-004964-32-GRKowa Research Europe, Ltd.96